Lisa Padilla, JD, LLM
CEO & CO-FOUNDER
Business/Tax Attorney, Angel Investor, Boston University, BS, LLM; Suffolk University, JD; Callen Lorde Community Health Center Board Member 2014 – Present (Audit, Finance and By-Laws Committees).
Dr. Alison Lukacsko
CSO & CO-FOUNDER
VP, GM and VP of Innovation, Research & Development, Georgia-Pacific, LLC; VP Business Development & R&D, Church & Dwight; Sr. Director and R&D Director Bristol-Myers Squibb (including women’s health).
Allison Drew Klein
DIRECTOR OF COMMUNITY RELATIONS
Pitney Bowes (30+ years, sales), Angel Investor.
MANAGEMENT TEAM & CO-FOUNDERS
The Beryl team brings passion, experience and knowledge to the development of treatments for bone disease. The company is harnessing the synergy of strong internal management, best in class advisors and leading contract research organizations.
SAB Chair (Beryl Health), Professor Dept. of Medicine and Chair of the Dept. of Oral Medicine, Infection, and Immunity, Harvard University.
Clinical scientist, osteoporosis specialist, endocrinologist, Prof. of Medicine Columbia University Medical School, & North American Co-Editor in Chief of Osteoporosis International. She investigated cyclic, combination & sequential regimens of teriparatide and antiresorptive agents; evaluated teriparatide’s effect on bone formation (human femur); lead contributor to pivotal studies of abaloparatide and romosozumab.
Javier San Martin
Former lead clinical development in bone, osteoporosis (Lilly, Amgen) and in rare diseases former lead for the development of FGF23 antibodies for XLH at Ultragenyx.
SCIENTIFIC ADVISORS: HUMAN PHARMACEUTICALS
Director of Research, Bone Laboratory at the Sackler Faculty of Medicine, Tel Aviv University. He is the co-author of one of Beryl's scientific publications on Prader-Willi Syndrome.
DVM, PhD, DACVP
Executive director, Amgen 2009-2017; Manager of Pathology Laboratory (Thousand Oaks); Nonclinical safety lead, denosumab and romosozumab; participated in writing of denosumab BLA and participation in advisory committee meetings; lead for nonclinical modules for romosozumab BLA and regulatory interactions.
SAB Chair, Associate Dean for Research; Professor; Director, Neuroscience Research Center at Medical College of Wisconsin.
MS, DACVS, ACVS Founding Fellow, Surgical Oncology, Director of the Columbine Health Systems Center for Healthy Aging.
Entrepreneur & Biotechnology leader at TeOno Perspectives; former Head of Nestle Institute of Health Sciences, VP of research & development of DFB Pharmaceuticals.
Entrepreneur, Scientific Advisor and Biotechnology Leader; CEO AvaChrome Inc. and former Director and Scientific Founder of the Nestle Institute of Health Sciences. Creator of science-driven companies and institutions for translational purposes. Areas of expertise include: cell therapy, endocrinology, metabolism, neurobiology, nutrition, regenerative medicine, omics and digital technologies.